Oncology

It is estimated that more than one in three people will develop some form of cancer during their lifetime. Therefore, early detection is very important. Our in-vitro immunological rapid tests are quick and reliable, helping in the diagnosis of common cancers such as bladder, colon, or prostate cancer.

 

Bladder cancer is the seventh most common cancer in the UK. There are more than twice as many cases of bladder cancer in men than in women.

After prostate cancer; bladder cancer is the second most common urological tumour and one of the most expensive cancers due to the lifelong care and treatment that is required.

The cure rate in bladder cancer, on average, is over 50% however, it has a high relapse rate of 70% making regular following-ups necessary for early detection of relapse.

The chances of recovery are highly dependent on the speed of diagnosis. When detected early, the bladder can often be saved. However in about 30% of patients upon initial diagnosis, the tumour is already in the muscular layer of the bladder. It is crucial for regular screening to detect bladder cancer before it becomes life threatening.

For this area, we offer the following rapid test:


Occult blood, or blood not visible in the stool (FOB, fecal occult blood), can point to various diseases (eg, polyps, fissures, diverticulitis). A particularly serious problem often leading to occult blood are colorectal carcinomas, these account for more than 95% of malignant colon tumors.

Through early detection of occult blood (human haemoglobin) in the faeces, it is possible to diagnose diseases of the colon in its early stages. This results in a timely treatment which is crucial, especially in colorectal cancer screening.

Through preventive screening for occult blood in the stool, the chance of recovery is increases significantly. Individuals who fall into the following categories should undertake precautionary screenings: elderly patients (over 50 years old), individuals with colon cancer in the family, alcohol consumption, smoking, obesity and lack of exercise.

For this area, we offer you our following rapid tests:

The alpha-fetoprotein (AFP) is a glycoprotein in human serum or plasma. It is produced during pregnancy by fetal yolk sac and fetal liver. In addition, it is also formed in tumor cells of the liver. A high concentration of AFP in men and non-pregnant women serves as a tumor marker for various cancers, such as a hepatocellular carcinoma (HCC).

PSA (Prostate Specific Antigen) is a protein that is produced by the prostate gland of males. The PSA value is measured in suspected and existing prostate cancer cells. It can also be monitored regularly as part of annual prostate cancer screening. However, the PSA level in many different prostate diseases can be increased, whether benign or malignant, when inflammation or infection of the prostate occurs.

The carcinoembryonic antigen (CEA) is a glycoprotein, which acts as a tumor marker for various cancers (colon cancer, pancreatic cancer, breast cancer, adenocarcinoma of the lung). CEA is produced in most cases of colon cancer cells and enters the blood. Since CEA is, however, made by other body cells, or even with benign diseases of different organs, it can cause a high CEA value which is not necessarily linked immediately to a colon cancer. As an early marker CEA is therefore only of limited use, whereas it is of great importance in the tumor after-care.

Helicobacter pylori (H. pylori) is a rod-shaped bacterium which establishes itself in the human stomach. It is responsible for a series of gastric diseases including type B gastritis, gastric ulcer, and duodenal ulcers. In the case of chronic infection with H. pylori, the patient is also at an increased risk for gastric cancer.

Due to the early detection of occult blood (human hemoglobin) in a stool sample, it is possible to diagnose a disease of the colon within the early stages. This allows timely treatment, which is crucial for bowel cancer prevention.

Through preventative screening for occult blood in the stool, chances of recovery increase significantly. People with the following risk factors should actively take preventative measures and regularly screen for the disease: older patients (starting at 50 years old), bowel cancer within the family, diet composing of meat and fat, alcohol consumption, smoking, obesity and little movement throughout the day.

For this field we offer the following rapid tests: